Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

144 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and tolerability of TOPROL-XL ® (metoprolol succinate) extended-release tablets (metoprolol CR/XL) in hypertensive pediatric subjects. The study population included school age children (age 6 to \< Tanner Stage 3) and adolescents (\> Tanner Stage 3 to age 16) of both genders. No more than 50% of the randomized subjects could be adolescents (\> Tanner Stage 3 to 16 years old). Since response to some therapies in adult hypertension appears to be different in black and non-black populations, recruitment was aimed at a mixture of black and non-black children. The design included a 1-week screening period (for treatment naive subjects), a 1-week single-blind placebo run-in period, and a 4-week double-blind treatment period. Eligible subjects were randomized to the double-blind period with a once daily oral dose of metoprolol CR/XL to one of three target doses: 0.2, 1.0 and 2.0 mg/kg, or placebo. Dosing was weight adjusted. The dose range for this study was 12.5 to 200 mg daily. Subjects were closely monitored and evaluated at the end of Weeks 1, 2, 3 and 4 during the double-blind treatment period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Factorial Study of Metoprolol Succinate TOPROL-XL (324A)

NCT00642096

High Blood Pressure (Hypertension).

COMPLETED PHASE3

Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension

NCT00861016

Hypertension

COMPLETED PHASE4

Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension

NCT06091176

Essential Hypertension Primary Hypertension

NOT_YET_RECRUITING NA

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

NCT02791438

Pediatric Hypertension

COMPLETED PHASE3

S-Metoprolol XR 25-50 mg Tablets vs Metoprolol Zok 50-100 mg Tablets in Hypertension Patients.

NCT04457323

Hypertension

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

metoprolol succinate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female between the ages of 6 and 16 years inclusive at the time of screening.
* Have a negative urine pregnancy test, if female of childbearing potential.
* Have a signed informed consent by a parent or a legal guardian and an assent form signed by the subject (if applicable).
* Have hypertension that is either:

1. Newly diagnosed and untreated with a mean sitting SBP or DBP above the 95 th percentile on three consecutive office visits, or
2. Previously diagnosed and currently treated with antihypertensive therapy at Visit 1, then at Visit 3 (off treatment) have a mean sitting SBP or DBP above the 95 th percentile.
* Have the ability to swallow tablets.

Exclusion Criteria

* Have secondary hypertension due to coarctation of aorta, pheochromocytoma, hyperthyroidism or Cushing's syndrome.
* Have SBP or DBP greater than 20 (SBP) or 10 (DBP) mm Hg above the 95th percentile using height adjusted charts for age and gender.
* Have a heart rate \< 55 beats per minute at randomization.
* Have a history of asthma and/or recurring pulmonary disease or infections.
* Have a history of cystic fibrosis.
* Have a known hypersensitivity reaction to beta-blockers.
* Have a known bleeding, coagulation or platelet disorder that can interfere with blood sampling.
* Have a history of Insulin Dependent Diabetes Mellitus.
* Be in any situation or have any condition which, in the opinion of the investigator or sponsor, may interfere with participation in the study or produce a significant risk to the subject or interfere with the assessment of safety and efficacy endpoints.
* Have received any investigational agent for any therapeutic reason within 30 days prior to receiving study medication.
* Have a clinically significant cardiac valvular disease.
* Have a diagnosis of heart failure.
* Have clinically significant arrhythmia. This is defined as any arrhythmia requiring medical therapy or that causes symptoms.
* Atrioventricular (AV) conduction disturbance, ie, second or third degree AV block.
* Be unable or unwilling to comply with the study requirements.
* Be non-compliant during the single-blind placebo run-in period of the study as defined by missing three or more doses between study visits.
* Have impaired liver function defined as either acute liver disease or chronic liver disease with persistent liver enzyme values greater than one and one half times the upper limit of the normal range for AST or ALT.
* Have a known history of bilateral renal artery stenosis, or unilateral renal artery stenosis to a single kidney. Nephrotic subjects who are not in remission should be excluded.
* Be pregnant or breast-feeding an infant.
* Currently taking medications known to inhibit CYP2D6, such as quinidine, fluoxetine, paroxetine and propafenone.
* Currently taking catecholamine-depleting medications such as reserpine. For any subject who is currently taking medications known to inhibit CYP2D6 or any catecholamine-depleting medication, the sponsor must be contacted to assess feasibility for inclusion into the study.
* Currently taking any selective serotonin re-uptake inhibitors (SSRIs) or atypical antipsychotic medication.
* Have a history of alcohol or drug abuse, or have a positive urine screen for drugs of abuse or alcohol.

Minimum Eligible Age

6 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No